Can a pretzel-shaped device rewrite the story of bladder cancer? In September 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo™ (formerly TAR-200), a novel intravesical gemcitabine delivery system developed by Johnson & Johnson for…
TrialX, in collaboration with investigators at the University of Iowa is proud to announce that the SAYSTOP Study App, developed to study antibiotic resistance using our remote data collection solution, has successfully completed enrollment. The “Study of…
When Ryan Frazier was only three months old, his family received life-changing news: he had acute myeloid leukemia (AML). Despite multiple rounds of chemotherapy, the cancer came back and spread to his central nervous system. His…
Imagine a world where studying cancer in space could help unlock new treatments on Earth. The Cancer in LEO-3 experiment aboard Axiom Mission 4 (Ax-4) investigated triple-negative breast cancer organoids to understand how microgravity affects tumor…
The 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research (September 16–17, 2025, Philadelphia, PA) brought together senior clinical operations executives, patient advocates, and technology leaders to explore the future of clinical trials. AI, patient-centric trial…
What happens to the human body when gravity disappears? Astronauts experience rapid cardiovascular and vestibular adaptation, which can cause dizziness, fainting, or impaired performance. The Ax-4 mission’s Telemetric Health AI (TESH) study captures these physiological changes…
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells controlling voluntary muscle movement. Each year, more than 5,000 people in the United States are diagnosed, and around 30,000 people are living…
